Michael Schmidt analyst at Guggenheim reiterates coverage on Mirati Therapeutics (MRTX) in the Healthcare sector with a Buy rating. TipRanks.com has Schmidt rated as a 4.9 star analyst with a 51% return on investment and a 22.8% success rate. Schmidt has set a price target of $ 115.
TipRanks.com reports that Mirati Therapeutics currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $146.78. The target pricing ranges from a high forecast of $208.00 down to a low forecast of $100.00. Mirati Therapeutics (MRTX)’s last closing price was $59.61 which would put the average price target at 140.90% upside.
In addition, TradingView issued a Sell rating for MRTX over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRTX.
Click here to get the full story >>
While we integrate our news with HealthTechMovers.com, if you are interested in the healthtech sector, please visit HealthTechMovers.com.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com. Another great tool for charting is TradingView.com, so you might want to check that out too.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.